

Ambros J Beer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10198139/publications.pdf>

Version: 2024-02-01

179
papers

12,270
citations

36303

51
h-index

26613

107
g-index

201
all docs

201
docs citations

201
times ranked

12329
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinicoanatomical substrates of selfish behaviour in amyotrophic lateral sclerosis – An observational cohort study. <i>Cortex</i> , 2022, 146, 261-270.	2.4	8
2	¹⁸ F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting. <i>Pathogens</i> , 2022, 11, 348.	2.8	1
3	Quantitative analysis of regional distribution of tau pathology with ¹¹ C-PBB3-PET in a clinical setting. <i>PLoS ONE</i> , 2022, 17, e0266906.	2.5	7
4	Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma. <i>Cancers</i> , 2022, 14, 2008.	3.7	14
5	Computed Tomography-Based Tumor Heterogeneity Analysis Reveals Differences in a Cohort with Advanced Pancreatic Carcinoma under Palliative Chemotherapy. <i>Visceral Medicine</i> , 2021, 37, 77-83.	1.3	2
6	FDG PET correlates weakly with HIF-1 α expression in solid tumors: a meta-analysis. <i>Acta Radiologica</i> , 2021, 62, 557-564.	1.1	4
7	Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in ¹⁷⁷ Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment. <i>Journal of Nuclear Medicine</i> , 2021, 62, 92-98.	5.0	13
8	Multiparametric PET and MRI of myocardial damage after myocardial infarction: correlation of integrin α ^v β ³ expression and myocardial blood flow. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1070-1080.	6.4	24
9	Important pharmacokinetic parameters for individualization of ¹⁷⁷ Lu-PSMA therapy: A global sensitivity analysis for a physiologically-based pharmacokinetic model. <i>Medical Physics</i> , 2021, 48, 556-568.	3.0	10
10	Tumor Vasculature. , 2021, , 831-867.		1
11	Mathematical Modeling of In Vivo Alpha Particle Generators and Chelator Stability. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, , .	1.0	5
12	Comparison of MRI-based and PET-based image pre-processing for quantification of ¹¹ C-PBB3 uptake in human brain. <i>Zeitschrift Fur Medizinische Physik</i> , 2021, 31, 37-47.	1.5	1
13	Changes of Radiation Treatment Concept Based on ⁶⁸ Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy. <i>Frontiers in Oncology</i> , 2021, 11, 665304.	2.8	7
14	A Whole-Body Physiologically Based Pharmacokinetic Model for Alpha Particle Emitting Bismuth in Rats. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, , .	1.0	2
15	Value of PET imaging for radiation therapy. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 326-343.	0.7	2
16	Value of PET imaging for radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1-23.	2.0	16
17	Comparison of Quantification of Target-Specific Accumulation of [¹⁸ F]-siPSMA-14 in the HET-CAM Model and in Mice Using PET/MRI. <i>Cancers</i> , 2021, 13, 4007.	3.7	10
18	First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.249029.	5.0	15

#	ARTICLE	IF	CITATIONS
19	There is a world beyond α -integrin: Multimeric ligands for imaging of the integrin subtypes $\alpha_2\beta_1$, $\alpha_5\beta_1$ and $\alpha_6\beta_1$ by positron emission tomography. <i>EJNMMI Research</i> , 2021, 11, 106.	2.5	14
20	An in silico study on the effect of the radionuclide half-life on PET/CT imaging with PSMA-targeting radioligands. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 33-37.	0.7	1
21	A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice. <i>Pharmaceutics</i> , 2021, 13, 2132.	4.5	9
22	A population-based method to determine the time-integrated activity in molecular radiotherapy. <i>EJNMMI Physics</i> , 2021, 8, 82.	2.7	10
23	Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands. <i>Scientific Reports</i> , 2020, 10, 16036.	3.3	17
24	Double-strand breaks in lymphocyte DNA of humans exposed to ^{18}F fluorodeoxyglucose and the static magnetic field in PET/MRI. <i>EJNMMI Research</i> , 2020, 10, 43.	2.5	4
25	Hepatic alveolar echinococcosis: correlation between computed tomography morphology and inflammatory activity in positron emission tomography. <i>Scientific Reports</i> , 2020, 10, 11808.	3.3	14
26	Combining Computed Tomography and Histology Leads to an Evolutionary Concept of Hepatic Alveolar Echinococcosis. <i>Pathogens</i> , 2020, 9, 634.	2.8	9
27	Multi-Modal PET and MR Imaging in the Hen α 's Egg Test-Chorioallantoic Membrane (HET-CAM) Model for Initial In Vivo Testing of Target-Specific Radioligands. <i>Cancers</i> , 2020, 12, 1248.	3.7	18
28	In vivo PET/MRI Imaging of the Chorioallantoic Membrane. <i>Frontiers in Physics</i> , 2020, 8, .	2.1	14
29	Interobserver variability, detection rate, and lesion patterns of ^{68}Ga -PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2339-2347.	6.4	26
30	Influence of sampling schedules on ^{177}Lu -PSMA dosimetry. <i>EJNMMI Physics</i> , 2020, 7, 41.	2.7	27
31	Diagnostic accuracy of intraoperative perfusion-weighted MRI and 5-aminolevulinic acid in relation to contrast-enhanced intraoperative MRI and ^{11}C -methionine positron emission tomography in resection of glioblastoma: a prospective study. <i>Neurosurgical Review</i> , 2019, 42, 471-479.	2.4	13
32	Modeling and Predicting Tumor Response in Radioligand Therapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 65-70.	5.0	41
33	Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands. <i>Nuclear Medicine and Biology</i> , 2019, 72-73, 20-25.	0.6	6
34	Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in ^{177}Lu -PSMA therapy. <i>Medical Physics</i> , 2019, 46, 5861-5866.	3.0	11
35	Quantitative DWI predicts event-free survival in children with neuroblastic tumours: preliminary findings from a retrospective cohort study. <i>European Radiology Experimental</i> , 2019, 3, 6.	3.4	10
36	Simple liver cysts and cystoid lesions in hepatic alveolar echinococcosis: a retrospective cohort study with Hounsfield analysis. <i>Parasite</i> , 2019, 26, 54.	2.0	14

#	ARTICLE	IF	CITATIONS
37	FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. <i>Translational Psychiatry</i> , 2019, 9, 54.	4.8	28
38	Can Met-PET/CT Predict Sporadic Multiglandular Hyperparathyroidism? Report of a Case and Review of the Literature. <i>Case Reports in Endocrinology</i> , 2019, 2019, 1-4.	0.4	1
39	Impact of rs12917 MGMT Polymorphism on [18F]FDG-PET Response in Pediatric Hodgkin Lymphoma (PHL). <i>Molecular Imaging and Biology</i> , 2019, 21, 1182-1191.	2.6	0
40	The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model. <i>Scientific Reports</i> , 2019, 9, 20041.	3.3	28
41	A simulation-based method to determine optimal sampling schedules for dosimetry in radioligand therapy. <i>Zeitschrift Fur Medizinische Physik</i> , 2019, 29, 314-325.	1.5	10
42	Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1694-1704.	6.4	23
43	The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for ¹⁷⁷ Lu-Labeled PSMA Peptides. <i>Journal of Nuclear Medicine</i> , 2018, 59, 929-933.	5.0	54
44	Workflow and Protocol Considerations. , 2018, , 151-168.		0
45	Diagnostic value of MRI-based 3D texture analysis for tissue characterisation and discrimination of low-grade chondrosarcoma from enchondroma: a pilot study. <i>European Radiology</i> , 2018, 28, 468-477.	4.5	62
46	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of A β species. <i>NeuroImage: Clinical</i> , 2018, 20, 603-610.	2.7	11
47	Treatment planning algorithm for peptide receptor radionuclide therapy considering multiple tumor lesions and organs at risk. <i>Medical Physics</i> , 2018, 45, 3516-3523.	3.0	15
48	18F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 10128-10134.	1.8	8
49	Response Evaluation in Head and Neck Oncology: Definition and Prediction. <i>Orl</i> , 2017, 79, 14-23.	1.1	7
50	Quantitative and correlative biodistribution analysis of ⁸⁹ Zr-labeled mesoporous silica nanoparticles intravenously injected into tumor-bearing mice. <i>Nanoscale</i> , 2017, 9, 9743-9753.	5.6	35
51	Editorial <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 284-285.	6.4	2
52	Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2179-2188.	6.4	35
53	Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2017, 7, 17038.	3.3	26
54	Is ¹¹ C-Methionine PET/CT Able to Localise Sestamibi-Negative Parathyroid Adenomas?. <i>World Journal of Surgery</i> , 2017, 41, 980-985.	1.6	31

#	ARTICLE	IF	CITATIONS
55	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 169-186.	27.6	792
56	Multiparametric ¹⁸ F-FDG PET/MR follow-up in a patient with autoimmune pancreatitis. <i>European Journal of Hybrid Imaging</i> , 2017, 1, 11.	1.5	2
57	¹¹ C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer. <i>Oncotarget</i> , 2017, 8, 66516-66527.	1.8	25
58	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- β 2 in a multicentre European memory clinic study. <i>Brain</i> , 2016, 139, 2540-2553.	7.6	107
59	Kidney, Urinary Tract, and Bladder. , 2016, , 875-915.		1
60	Inpatient Comparison of ¹¹¹ In-PSMA I&T SPECT/CT and Hybrid ⁶⁸ Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, e397-e402.	1.3	45
61	Diffusion-weighted imaging outside the brain: Consensus statement from an ISMRM-sponsored workshop. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 521-540.	3.4	146
62	Value of ⁶⁸ Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1713-1719.	5.0	213
63	Simultaneous ⁶⁸ Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. <i>European Urology</i> , 2016, 70, 829-836.	1.9	456
64	Optimized Peptide Amount and Activity for ⁹⁰ Y-Labeled DOTATATE Therapy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 503-508.	5.0	45
65	Diagnostic Efficacy of ⁶⁸ Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. <i>Journal of Urology</i> , 2016, 195, 1436-1443.	0.4	659
66	In vivo biokinetic and metabolic characterization of the ⁶⁸ Ga-labelled β -selective peptidomimetic FR366. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 953-963.	6.4	22
67	Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for ¹⁷⁷ Lu-Labeled PSMA-Targeting Peptides. <i>PLoS ONE</i> , 2016, 11, e0162303.	2.5	30
68	Non-invasive assessment of inter-and inpatient variability of integrin expression in metastasized prostate cancer by PET. <i>Oncotarget</i> , 2016, 7, 28151-28159.	1.8	18
69	<i>In vivo</i> molecular imaging of chemokine receptor <i>CXCR</i> 4 expression in patients with advanced multiple myeloma. <i>EMBO Molecular Medicine</i> , 2015, 7, 477-487.	6.9	180
70	PD32-06 DETECTION RATES OF ⁶⁸ GALLIUM-LABELLED LIGAND OF PSMA PET/CT AND PET/MRI IN 332 CONSECUTIVE PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2015, 193, .	0.4	0
71	Visualization of stress fractures of the foot using PET-MRI: a feasibility study. <i>European Journal of Medical Research</i> , 2015, 20, 99.	2.2	22
72	Comparative Oncology: Evaluation of 2-Deoxy-2-[¹⁸ F]fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors. <i>PLoS ONE</i> , 2015, 10, e0127800.	2.5	17

#	ARTICLE	IF	CITATIONS
73	Physiologically Based Pharmacokinetic Modeling Is Essential in ⁹⁰ Y-Labeled Anti-CD66 Radioimmunotherapy. PLoS ONE, 2015, 10, e0127934.	2.5	20
74	Multiparametric MR and PET Imaging of Intratumoral Biological Heterogeneity in Patients with Metastatic Lung Cancer Using Voxel-by-Voxel Analysis. PLoS ONE, 2015, 10, e0132386.	2.5	28
75	Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging. Theranostics, 2015, 5, 618-630.	10.0	162
76	Imaging of Tumor Angiogenesis for Radiologistsâ€”Part 1: Biological and Technical Basis. Current Problems in Diagnostic Radiology, 2015, 44, 407-424.	1.4	45
77	Imaging of Tumor Angiogenesis for Radiologistsâ€”Part 2: Clinical Utility. Current Problems in Diagnostic Radiology, 2015, 44, 425-436.	1.4	15
78	Population-Based Modeling Improves Treatment Planning Before ⁹⁰ Y-Labeled Anti-CD66 Antibody Radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 285-290.	1.0	6
79	Evaluation of ¹⁸ F-Fluoride PET/MR and PET/CT in Patients with Foot Pain of Unclear Cause. Journal of Nuclear Medicine, 2015, 56, 430-435.	5.0	25
80	Radiofluorination of PSMA-HBED via Al ¹⁸ F ²⁺ Chelation and Biological Evaluations In Vitro. Molecular Imaging and Biology, 2015, 17, 777-785.	2.6	44
81	Evaluation of Hybrid ⁶⁸ Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. Journal of Nuclear Medicine, 2015, 56, 668-674.	5.0	907
82	Combined PET/MRI: Multi-modality Multi-parametric Imaging Is Here. Molecular Imaging and Biology, 2015, 17, 595-608.	2.6	56
83	Drug-induced cerebral glucose metabolism resembling Alzheimerâ€™s Disease: a case study. BMC Psychiatry, 2015, 15, 157.	2.6	8
84	Discrimination Between Brown and White Adipose Tissue Using a 2-Point Dixon Waterâ€”Fat Separation Method in Simultaneous PET/MRI. Journal of Nuclear Medicine, 2015, 56, 1742-1747.	5.0	45
85	PET imaging with ⁶⁸ Gallium-labelled ligand of prostate-specific membrane antigen (⁶⁸ Ga-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy.. Journal of Clinical Oncology, 2015, 33, 5023-5023.	1.6	5
86	PET imaging with of prostate-specific membrane antigen (PSMA) for staging of primary prostate cancer with ⁶⁸ Ga-HBED-PSMA.. Journal of Clinical Oncology, 2015, 33, e16038-e16038.	1.6	3
87	Multimodality Multiparametric Imaging of Early Tumor Response to a Novel Antiangiogenic Therapy Based on Anticalins. PLoS ONE, 2014, 9, e94972.	2.5	13
88	Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma. OncoTargets and Therapy, 2014, 7, 1123.	2.0	7
89	Positron emission tomography/magnetic resonance imaging with ⁶⁸ G ⁺ alliumâ€”labeled ligand of prostateâ€”specific membrane antigen: Promising novel option in prostate cancer imaging?. International Journal of Urology, 2014, 21, 1286-1288.	1.0	23
90	Limited-projection-angle hybrid fluorescence molecular tomography of multiple molecules. Journal of Biomedical Optics, 2014, 19, 046016.	2.6	8

#	ARTICLE	IF	CITATIONS
91	Diagnostic value of retrospective PET-MRI fusion in head-and-neck cancer. BMC Cancer, 2014, 14, 846.	2.6	29
92	PET/MR in Oncology: Non- ¹⁸ F-FDG Tracers for Routine Applications. Journal of Nuclear Medicine, 2014, 55, 25S-31S.	5.0	15
93	Prognostic Value of ¹¹ C-Choline PET/CT and CT for Predicting Survival of Bladder Cancer Patients Treated with Radical Cystectomy. Urologia Internationalis, 2014, 93, 207-213.	1.3	19
94	MP42-18 IMAGING OF RECURRENT PROSTATE CANCER USING ⁶⁸ GALLIUM-LABELLED LIGAND OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN PET/CT AND PET/MRI. Journal of Urology, 2014, 191, .	0.4	0
95	PET/CT Imaging of Integrin α _v β ₃ Expression in Human Carotid Atherosclerosis. JACC: Cardiovascular Imaging, 2014, 7, 178-187.	5.3	145
96	PET/MR Imaging in the Detection and Characterization of Pulmonary Lesions: Technical and Diagnostic Evaluation in Comparison to PET/CT. Journal of Nuclear Medicine, 2014, 55, 724-729.	5.0	113
97	Multimodal Molecular Imaging of Integrin α _v β ₃ for In Vivo Detection of Pancreatic Cancer. Journal of Nuclear Medicine, 2014, 55, 446-451.	5.0	43
98	Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and ¹¹ C-choline PET/CT. European Radiology, 2014, 24, 1821-1826.	4.5	41
99	MP42-08 STAGING OF INTERMEDIATE AND HIGH-RISK PROSTATE CANCER USING WHOLE BODY ⁶⁸ GALLIUM-LABELLED LIGAND OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN PET/MRI. Journal of Urology, 2014, 191, .	0.4	2
100	Performance of Whole-Body Integrated ¹⁸ F-FDG PET/MR in Comparison to PET/CT for Evaluation of Malignant Bone Lesions. Journal of Nuclear Medicine, 2014, 55, 191-197.	5.0	134
101	Systematic Comparison of the Performance of Integrated Whole-Body PET/MR Imaging to Conventional PET/CT for ¹⁸ F-FDG Brain Imaging in Patients Examined for Suspected Dementia. Journal of Nuclear Medicine, 2014, 55, 923-931.	5.0	46
102	Potential clinical implications of <i>BRAF</i> mutations in histiocytic proliferations. Oncotarget, 2014, 5, 4060-4070.	1.8	78
103	[⁶⁸ Ga]Pentixafor: A Novel PET Tracer for Imaging CXCR4 Status in Patients with Multiple Myeloma. Blood, 2014, 124, 2014-2014.	1.4	3
104	PET/MR in prostate cancer: technical aspects and potential diagnostic value. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 79-88.	6.4	49
105	Comparison of integrated whole-body [¹¹ C]choline PET/MR with PET/CT in patients with prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1486-1499.	6.4	107
106	Sensitivity of PET/MRI to detect recurrence of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 799-799.	6.4	14
107	¹⁸ F-Fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. Cancer, 2013, 119, 1227-1234.	4.1	44
108	Bone mineral density measurements of the proximal femur from routine contrast-enhanced MDCT data sets correlate with dual-energy X-ray absorptiometry. European Radiology, 2013, 23, 505-512.	4.5	24

#	ARTICLE	IF	CITATIONS
109	Three-dimensional Magnetic Resonance Imaging Using Single Breath-hold k-t BLAST for Assessment of Global Left Ventricular Functional Parameters. <i>Academic Radiology</i> , 2013, 20, 987-994.	2.5	11
110	Current Staging Procedures in Urinary Bladder Cancer. <i>Diagnostics</i> , 2013, 3, 315-324.	2.6	9
111	Selective Imaging of the Angiogenic Relevant Integrins $\alpha_5\beta_1$ and $\alpha_v\beta_3$. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 11656-11659.	13.8	43
112	Evaluation of Feasibility and Image Quality of 68Ga-DOTATOC Positron Emission Tomography/Magnetic Resonance in Comparison With Positron Emission Tomography/Computed Tomography in Patients With Neuroendocrine Tumors. <i>Investigative Radiology</i> , 2013, 48, 263-272.	6.2	55
113	Changes in the tumor glucose-uptake measured by 18F-FDG PET with two weeks of single-agent cetuximab in localized squamous cell carcinoma of the esophagus. <i>Journal of Clinical Oncology</i> , 2013, 31, e15042-e15042.	1.6	0
114	PET/MR imaging of atherosclerosis: initial experience and outlook. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 3, 393-6.	1.0	16
115	Inversion-recovery single-shot cardiac MRI for the assessment of myocardial infarction at 1.5 T with a dedicated cardiac coil. <i>British Journal of Radiology</i> , 2012, 85, e709-e715.	2.2	4
116	Workflow and Scan Protocol Considerations for Integrated Whole-Body PET/MRI in Oncology. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1415-1426.	5.0	109
117	First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic Diagnoses. <i>Journal of Nuclear Medicine</i> , 2012, 53, 845-855.	5.0	466
118	A Case of Multimodality Multiparametric 11C-Choline PET/MR for Biopsy Targeting in Prior Biopsy-Negative Primary Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2012, 37, 918-919.	1.3	13
119	Simulation of a MR-PET protocol for staging of head-and-neck cancer including Dixon MR for attenuation correction. <i>European Journal of Radiology</i> , 2012, 81, 2658-2665.	2.6	31
120	68Ga-NODAGA-RGD is a suitable substitute for 18F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. <i>Nuclear Medicine and Biology</i> , 2012, 39, 777-784.	0.6	93
121	Radiolabelled RGD peptides for imaging and therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 126-138.	6.4	203
122	Comparison of 3-deoxy-3-[18F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 846-851.	6.4	51
123	Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. <i>European Radiology</i> , 2012, 22, 1465-1478.	4.5	17
124	PET-MRI Fusion in Head-and-Neck Oncology: Current Status and Implications for Hybrid PET/MRI. <i>Journal of Oral and Maxillofacial Surgery</i> , 2012, 70, 473-483.	1.2	69
125	PET/CT for the diagnosis, staging and restaging of prostate cancer. <i>Imaging in Medicine</i> , 2011, 3, 571-585.	0.0	4
126	Pancreatic and Hepatobiliary Cancers. <i>Methods in Molecular Biology</i> , 2011, 727, 243-264.	0.9	2

#	ARTICLE	IF	CITATIONS
127	Radionuclide and hybrid imaging of recurrent prostate cancer. <i>Lancet Oncology</i> , The, 2011, 12, 181-191.	10.7	94
128	Magnetic resonance imaging of myocardial injury and ventricular torsion after marathon running. <i>Clinical Science</i> , 2011, 120, 143-152.	4.3	55
129	Characterization of carotid artery plaques with USPIO-enhanced MRI: assessment of inflammation and vascularity as in vivo imaging biomarkers for plaque vulnerability. <i>International Journal of Cardiovascular Imaging</i> , 2011, 27, 901-912.	1.5	37
130	Restricted Water Diffusibility as Measured by Diffusion-weighted MR Imaging and Choline Uptake in 11C-Choline PET/CT are Correlated in Pelvic Lymph Nodes in Patients with Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2011, 13, 352-361.	2.6	61
131	Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1691-1701.	6.4	161
132	Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: Technical feasibility and assessment of lesion conspicuity in DWI. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 33, 1160-1170.	3.4	83
133	PET of α^23 -Integrin and α^25 -Integrin Expression with 18F-Fluciclatide for Assessment of Response to Targeted Therapy: Ready for Prime Time?. <i>Journal of Nuclear Medicine</i> , 2011, 52, 335-337.	5.0	14
134	PET Imaging of α^23 Expression in Cancer Patients. <i>Methods in Molecular Biology</i> , 2011, 680, 183-200.	0.9	23
135	PET Imaging of Integrin α^23 Expression. <i>Theranostics</i> , 2011, 1, 48-57.	10.0	117
136	Preliminary Results for Characterization of Pelvic Lymph Nodes in Patients With Prostate Cancer by Diffusion-Weighted MR-Imaging. <i>Investigative Radiology</i> , 2010, 45, 15-23.	6.2	143
137	Non-invasive tracking of human haemopoietic CD34+ stem cells in vivo in immunodeficient mice by using magnetic resonance imaging. <i>European Radiology</i> , 2010, 20, 2184-2193.	4.5	23
138	Imaging of angiogenesis: from morphology to molecules and from bench to bedside. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1-3.	6.4	8
139	Positron emission tomography tracers for imaging angiogenesis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 86-103.	6.4	102
140	Phenotyping of Tumor Biology in Patients by Multimodality Multiparametric Imaging: Relationship of Microcirculation, α^23 Expression, and Glucose Metabolism. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1691-1698.	5.0	39
141	Alternative PET Tracers in Musculoskeletal Disease. <i>PET Clinics</i> , 2010, 5, 363-374.	3.0	3
142	PET imaging of gliomas using novel tracers: a sleeping beauty waiting to be kissed. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 609-613.	2.4	21
143	Molecular Imaging of Angiogenesis. , 2010, , 105-115.		0
144	Application of RGD-containing peptides as imaging probes for α^3 expression. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 887.	3.0	69

#	ARTICLE	IF	CITATIONS
145	Multimodal Tumor Therapy in a 31-Year-Old Pregnant Woman with Wilms Tumor. <i>Urologia Internationalis</i> , 2009, 83, 364-367.	1.3	5
146	Demonstration of metastatic tumour growth following vessel structures by PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1021-1021.	6.4	1
147	Assessment of Tumor Volumes in Skull Base Glomus Tumors Using Gluc-Lys[18F]-TOCA Positron Emission Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1135-1140.	0.8	19
148	Imaging of integrin $\alpha v \beta 3$ expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. <i>Neuro-Oncology</i> , 2009, 11, 861-870.	1.2	180
149	Imaging of integrin $\alpha v \beta 3$ expression. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 631-644.	5.9	208
150	PET/CT with Gluc-Lys-([18F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 264-271.	6.4	16
151	Dynamics of retronasal aroma perception during consumption: Cross-linking on-line breath analysis with medico-analytical tools to elucidate a complex process. <i>Food Chemistry</i> , 2008, 108, 1234-1246.	8.2	51
152	Visualization of antigen-specific human cytotoxic T lymphocytes labeled with superparamagnetic iron-oxide particles. <i>European Radiology</i> , 2008, 18, 1087-1095.	4.5	16
153	Expression of Integrin $\alpha v \beta 3$ in Gliomas Correlates with Tumor Grade and Is not Restricted to Tumor Vasculature. <i>Brain Pathology</i> , 2008, 18, 378-386.	4.1	161
154	Patterns of $\alpha v \beta 3$ Expression in Primary and Metastatic Human Breast Cancer as Shown by ^{18}F -Galacto-RGD PET. <i>Journal of Nuclear Medicine</i> , 2008, 49, 255-259.	5.0	170
155	Comparison of Integrin $\alpha v \beta 3$ Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using ^{18}F -Galacto-RGD and ^{18}F -FDG. <i>Journal of Nuclear Medicine</i> , 2008, 49, 22-29.	5.0	173
156	SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1305-1319.	5.0	280
157	Prospective study on bright lumen magnetic resonance colonography in comparison with conventional colonoscopy. <i>British Journal of Radiology</i> , 2007, 80, 235-241.	2.2	24
158	Rectal Cancer: MR Imaging before Neoadjuvant Chemotherapy and Radiation Therapy for Prediction of Tumor-Free Circumferential Resection Margins and Long-term Survival. <i>Radiology</i> , 2007, 243, 744-751.	7.3	63
159	[18F]Galacto-RGD Positron Emission Tomography for Imaging of $\alpha v \beta 3$ Expression on the Neovasculature in Patients with Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2007, 13, 6610-6616.	7.0	217
160	Comparison of 16-MDCT and MRI for Characterization of Kidney Lesions. <i>American Journal of Roentgenology</i> , 2006, 186, 1639-1650.	2.2	38
161	2388. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, S425-S426.	0.8	1
162	Ferumoxtran-10-enhanced MR imaging of the bone marrow before and after conditioning therapy in patients with non-Hodgkin lymphomas. <i>European Radiology</i> , 2006, 16, 598-607.	4.5	38

#	ARTICLE	IF	CITATIONS
163	[111In]DOTATOC as a dosimetric substitute for kidney dosimetry during [90Y]DOTATOC therapy: results and evaluation of a combined gamma camera/probe approach. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1328-1336.	6.4	3
164	Adenocarcinomas of Esophagogastric Junction: Multi-Phase Detector Row CT to Evaluate Early Response to Neoadjuvant Chemotherapy. <i>Radiology</i> , 2006, 239, 472-480.	7.3	81
165	Rectal Carcinoma: High-Spatial-Resolution MR Imaging and T2 Quantification in Rectal Cancer Specimens. <i>Radiology</i> , 2006, 241, 132-141.	7.3	30
166	Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin $\alpha v \beta 3$ Expression in Man. <i>Clinical Cancer Research</i> , 2006, 12, 3942-3949.	7.0	337
167	PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging $\alpha v \beta 3$ expression. <i>Journal of Nuclear Medicine</i> , 2006, 47, 763-9.	5.0	109
168	Noninvasive Visualization of the Activated $\alpha v \beta 3$ Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD. <i>PLoS Medicine</i> , 2005, 2, e70.	8.4	443
169	Biodistribution and pharmacokinetics of the $\alpha v \beta 3$ -selective tracer 18F-galacto-RGD in cancer patients. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1333-41.	5.0	202
170	Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment. <i>Journal of Clinical Oncology</i> , 2004, 22, 900-908.	1.6	448
171	MR cystography for bladder tumor detection. <i>European Radiology</i> , 2004, 14, 2311-2319.	4.5	32
172	Magnetic resonance colonography: A promising new technique. <i>Current Gastroenterology Reports</i> , 2004, 6, 389-394.	2.5	3
173	Dynamic near-real-time magnetic resonance imaging for analyzing the velopharyngeal closure in comparison with videofluoroscopy. <i>Journal of Magnetic Resonance Imaging</i> , 2004, 20, 791-797.	3.4	49
174	High-resolution MRI vs multislice spiral CT: Which technique depicts the trabecular bone structure best?. <i>European Radiology</i> , 2003, 13, 663-671.	4.5	114
175	Tumors of the urinary bladder: technique, current use, and perspectives of MR and CT cystography. <i>Abdominal Imaging</i> , 2003, 28, 868-76.	2.0	20
176	Reliability of MR Imaging-Based Virtual Cystoscopy in the Diagnosis of Cancer of the Urinary Bladder. <i>American Journal of Roentgenology</i> , 2002, 178, 1483-1488.	2.2	80
177	Quantitation of the In-Mouth Release of Heteroatomic Odorants. <i>ACS Symposium Series</i> , 2002, , 296-311.	0.5	3
178	Physiological and analytical studies on flavor perception dynamics as induced by the eating and swallowing process. <i>Food Quality and Preference</i> , 2002, 13, 497-504.	4.6	109
179	Observation of the Swallowing Process by Application of Videofluoroscopy and Real-time Magnetic Resonance Imaging—Consequences for Retronasal Aroma Stimulation. <i>Chemical Senses</i> , 2001, 26, 1211-1219.	2.0	192